WP
SPRY icon

Woodline Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Woodline Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-150,936
Closed -$1.76M – 1145
2025
Q4 		$1.76M Hold
150,936
– – 0.01% 784
2025
Q3 		$1.52M Sell
150,936
-149,483
-50% -$2.15M 0.01% 760
2025
Q2 		$5.24M Sell
300,419
-299,903
-50% -$4.33M 0.03% 549
2025
Q1 		$7.55M Sell
600,322
-518,961
-46% -$6.24M 0.05% 411
2024
Q4 		$11.8M Buy
1,119,283
+133,276
+14% +$1.87M 0.08% 308
2024
Q3 		$14.3M Buy
986,007
+704,863
+251% +$8.38M 0.12% 234
2024
Q2 		$2.39M Sell
281,144
-120,644
-30% -$1.07M 0.02% 406
2024
Q1 		$4.11M Sell
401,788
-259,626
-39% -$1.94M 0.04% 380
2023
Q4 		$3.62M Sell
661,414
-185,640
-22% -$813K 0.04% 343
2023
Q3 		$3.2M Buy
847,054
+176,967
+26% +$1.16M 0.04% 357
2023
Q2 		$4.49M Buy
670,087
+70,087
+12% +$468K 0.05% 308
2023
Q1 		$3.91M Sell
600,000
-661,307
-52% -$5.08M 0.05% 328
2022
Q4 		$10.8M Buy
1,261,307
+448,408
+55% +$2.91M 0.14% 194
2022
Q3 		$4.29M Buy
+812,899
New +$4.01M 0.06% 330
2022
Q2 		– Sell
-83,571
Closed -$293K – 881
2022
Q1 		$293K Sell
83,571
-410,324
-83% -$1.79M ﹤0.01% 535
2021
Q4 		$3.29M Buy
493,895
+68,634
+16% +$558K 0.05% 344
2021
Q3 		$4.24M Buy
425,261
+47,630
+13% +$1.17M 0.07% 279
2021
Q2 		$11.7M Buy
377,631
+170,948
+83% +$5.48M 0.22% 119
2021
Q1 		$9.02M Sell
206,683
-8,853
-4% -$419K 0.2% 129
2020
Q4 		$9.99M Buy
+215,536
New +$7.2M 0.26% 116

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Woodline Partners's SPRY Position: Q1 2026 in Review

Woodline Partners sold out of ARS Pharmaceuticals (SPRY) in Q1 2026, closing a stake of 150,936 shares — an estimated $1.76M sold.

Woodline Partners first reported a position in SPRY in Q4 2020 and held it in 20 quarters. The position peaked at $14.3M in Q3 2024. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Woodline Partners reported no remaining ARS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Woodline Partners sold 150,936 ARS Pharmaceuticals shares in Q1 2026, an estimated $1.76M.
  • Woodline Partners first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 20 quarters.
  • Woodline Partners's ARS Pharmaceuticals position peaked at $14.3M in Q3 2024.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.